Gratus Capital LLC Sells 631 Shares of Abbott Laboratories (ABT)
Gratus Capital LLC reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 0.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 165,697 shares of the healthcare product maker’s stock after selling 631 shares during the period. Gratus Capital LLC’s holdings in Abbott Laboratories were worth $6,364,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in the stock. State Street Corp boosted its position in shares of Abbott Laboratories by 2.4% in the fourth quarter. State Street Corp now owns 67,692,934 shares of the healthcare product maker’s stock valued at $2,600,094,000 after buying an additional 1,562,649 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Abbott Laboratories by 11.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 32,791,216 shares of the healthcare product maker’s stock valued at $1,386,741,000 after buying an additional 3,272,839 shares in the last quarter. BlackRock Fund Advisors boosted its position in Abbott Laboratories by 3.9% in the third quarter. BlackRock Fund Advisors now owns 23,656,893 shares of the healthcare product maker’s stock valued at $1,000,450,000 after buying an additional 878,861 shares in the last quarter. Northern Trust Corp boosted its position in Abbott Laboratories by 9.4% in the third quarter. Northern Trust Corp now owns 22,494,731 shares of the healthcare product maker’s stock valued at $951,303,000 after buying an additional 1,937,416 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in Abbott Laboratories by 13.6% in the third quarter. TIAA CREF Investment Management LLC now owns 11,557,232 shares of the healthcare product maker’s stock valued at $488,755,000 after buying an additional 1,385,598 shares in the last quarter. 62.20% of the stock is currently owned by institutional investors and hedge funds.
Shares of Abbott Laboratories (NYSE:ABT) opened at 44.98 on Tuesday. The stock’s 50 day moving average is $44.15 and its 200 day moving average is $41.25. The stock has a market cap of $77.73 billion, a price-to-earnings ratio of 48.00 and a beta of 0.97. Abbott Laboratories has a 52 week low of $36.76 and a 52 week high of $45.84.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Monday, February 6th. The healthcare product maker reported $0.65 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.65. The business had revenue of $5.33 billion for the quarter, compared to analysts’ expectations of $5.41 billion. Abbott Laboratories had a net margin of 6.71% and a return on equity of 15.74%. The business’s revenue was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.62 earnings per share. On average, equities analysts forecast that Abbott Laboratories will post $2.45 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, May 15th. Shareholders of record on Friday, April 14th will be issued a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a yield of 2.36%. The ex-dividend date of this dividend is Tuesday, April 11th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 113.98%.
Your IP Address:
ABT has been the topic of several recent analyst reports. TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Wednesday, March 8th. Jefferies Group LLC reissued a “buy” rating and set a $51.00 target price on shares of Abbott Laboratories in a research report on Friday, February 17th. Royal Bank of Canada lifted their target price on shares of Abbott Laboratories from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 1st. BMO Capital Markets cut shares of Abbott Laboratories from an “outperform” rating to a “market perform” rating and set a $48.00 target price on the stock. in a research report on Tuesday, March 14th. Finally, Zacks Investment Research cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, January 11th. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $48.27.
In other Abbott Laboratories news, VP Robert E. Funck sold 25,500 shares of the company’s stock in a transaction dated Thursday, February 23rd. The shares were sold at an average price of $45.50, for a total value of $1,160,250.00. Following the sale, the vice president now owns 117,579 shares in the company, valued at $5,349,844.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Michael J. Warmuth sold 3,851 shares of the company’s stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $45.39, for a total transaction of $174,796.89. The disclosure for this sale can be found here. In the last 90 days, insiders sold 78,592 shares of company stock worth $3,400,139. Corporate insiders own 0.26% of the company’s stock.
Abbott Laboratories Company Profile
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.